Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

Parabilis Medicines CEO Mathai Mammen, M.D., Ph.D., told Fierce the industry had been in “retreat mode for some time” before its latest rebound. (mesh cube/iStock/Getty Images Plus) Elon Musk's SpaceX ...

In its annual Biotech Beyond Borders report, EY projects growth to continue throughout 2026, fueled primarily by the increased volume and value of M&A and licensing deals. (Techa Tungateja/GettyImages ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

Alexander Lobrano is a well-known Paris restaurant expert, has written Eater’s best restaurants map to Paris since 2016, and is the author of Hungry for Paris, Hungry for France, and My Place at the ...

The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in ‌fields ranging from oncology and neurology to rare ...

Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming ...

Discover the latest in biotechnology with press releases highlighting innovations, research, and developments driving biotech's future. Stay informed on advancements changing biotech and explore ...